Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,714 total articles
Oncolytics Biotech announced FDA alignment on the design of a pivotal randomized controlled trial for pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal who have exhausted standard treatments. The trial aims to support both accelerated and full approval based on multiple endpoints. Previous studies show pr…
iRhythm Holdings announced new data presented at HRS 2026 showing that short-term Holter monitoring (24-48 hours) misses a significant proportion of atrial fibrillation (AF) recurrences post-ablation and clinically significant arrhythmias during pregnancy. Their Zio ambulatory ECG device, offering continuous monitoring up to 14 days, demonstrated s…
Terns Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to TERN-701, an oral allosteric BCR::ABL1 inhibitor targeting adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. This designation recognizes TERN-701's potential to offer substantial clinical improvement i…
Business First Bancshares, Inc. announced its Q1 2026 financial results, reporting net income available to common shareholders of $22.2 million ($0.68 per diluted share). The quarter included the consummation of the acquisition of Progressive Bancorp, Inc., adding significant assets and banking centers. The company also formed a strategic partnersh…
Ardelyx announced acceptance of an abstract for a poster presentation at the National Kidney Foundation's Spring Clinical Meetings, showcasing data on the long-term impact of XPHOZAH (tenapanor) on serum electrolytes and nutrition biomarkers in chronic kidney disease patients on dialysis. The presentation and related peer exchange emphasize XPHOZAH…
Iovance Biotherapeutics will report its first quarter 2026 financial results and provide corporate updates via a conference call and live webcast on May 7, 2026. The company focuses on developing tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, including the FDA-approved Amtagvi® therapy.
Safe Pro Group Inc., a Nasdaq-listed AI defense technology firm, will demonstrate its NODE-X AI edge platform and SPOTD threat detection technology at the U.S. Army's 2026 Joint Protection Combined Expo. These advanced AI tools enable rapid drone image processing for mission planning, threat detection, 3D mapping, and enhanced battlefield situation…
Townsquare Media announced a strategic digital advertising partnership with North American Broadcasting Company (NABCO), extending its digital ad solutions to more large markets via NABCO's radio broadcast platforms. This partnership is part of Townsquare's Media Partnerships initiative under Townsquare Ignite, aiming to grow digital revenue and pr…
Avalyn Pharma has strengthened its leadership team by appointing Adam Golden as General Counsel and Head of Business Development, and Frank Salisbury as Senior Vice President of Commercial. These hires bring significant legal, business development, and commercial experience to support Avalyn's clinical advancement and upcoming transition to a publi…
Commerce (Nasdaq: CMRC) has introduced Feedonomics Agentic Catalog Exports (ACE), an enterprise service enabling merchants to syndicate optimized product catalogs to AI-powered agentic discovery platforms such as OpenAI and Google Gemini. This innovation supports enterprises in becoming 'agent-ready' for AI-driven shopping experiences, reducing eng…
Replimune Group, Inc. announced multiple oral and poster presentations for the upcoming 2026 ASCO Annual Meeting, highlighting key clinical trial results from their oncolytic immunotherapy candidates RP1 and RP2 in treating melanoma and advanced solid tumors. Notably, a 3-year overall survival analysis from the IGNYTE trial and final Phase 1 data o…
Magnite announced a significant upgrade of its AI-powered features in its SpringServe platform, introducing intelligent mediation tools such as anomaly detection, demand path optimization, and dynamic pricing to enhance media owners' monetization strategies. Concurrently, Magnite is advancing AI-driven buyer agent tools to streamline campaign activ…
Westwood Holdings Group announced a strategic partnership with ETF Capital Markets Advisors, led by industry veteran Nicholas Phillips, to optimize trading efficiency, liquidity, and execution quality across its ETF platform. This collaboration aims to deepen market maker and authorized participant relationships and improve investor outcomes throug…
Strive, Inc. has purchased an additional approximately 789 Bitcoin, bringing its total holdings to around 14,557 Bitcoin. The company also announced the 'Bitcoin for Business' summit in Lake Oswego, designed to educate CFOs and business leaders about Bitcoin's impact on corporate finance. Strive focuses on disciplined capital allocation with Bitcoi…
SBC Medical Group Holdings Incorporated announces the full rollout of its aesthetic healthcare interpretation app "Talk Bridge" across all Shonan Beauty Clinic locations. The initiative enhances English-speaking customer support with in-house interpretation services, the creation of the Global Beauty Advisor role, and upgraded English digital marke…
Global-e Online Ltd., a leading platform for global direct-to-consumer e-commerce, announced it will report its financial results for the first quarter ending March 31, 2026, before the market opens on May 13, 2026. The company will host a conference call and webcast to discuss the results and outlook.
Arcutis Biotherapeutics has submitted a supplemental New Drug Application to the FDA seeking approval to expand the indication of its topical therapy ZORYVE® (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months. This submission is supported by positive Phase 1 and Phase 2 clinical tri…
Belite Bio announced an upcoming oral presentation of positive topline results from its Phase 3 DRAGON trial evaluating tinlarebant for Stargardt disease type 1 (STGD1). Tinlarebant showed a significant 35.7% reduction in the growth of atrophic retinal lesions compared to placebo, with a strong safety profile. The therapy targets accumulation of bi…
Kratos Defense & Security Solutions, a Nasdaq-listed technology company serving defense and national security sectors, announced its first quarter 2026 earnings release and conference call scheduled for May 6th. Management will discuss financial results and operational updates, reflecting ongoing activities in defense technology and advanced system…
Humacyte, Inc. announced a virtual key opinion leader event to discuss its Acellular Tissue Engineered Vessel (ATEV) designed for arteriovenous (AV) access in hemodialysis patients. The event will feature leading experts discussing unmet medical needs, current treatment limitations with AV fistulas, and insights on clinical trials including an ongo…
Alpha Compute Corp. provided an update on its NVIDIA Blackwell GPU infrastructure deployments. The company is finalizing testing of its first large-scale GPU cluster (ALPHA-01) consisting of 504 NVIDIA B200 GPUs in Canada, targeting a May 8, 2026 go-live. Despite a delay from March due to supply chain issues, the deployment marks the transition fro…
Microchip Technology announced the opening of a new manufacturing facility in Tuscaloosa, Alabama dedicated to increasing production of its MHM-2020 Active Hydrogen Maser, a highly precise atomic clock used in critical infrastructure and scientific applications. The expansion is aimed at meeting rising global demand and reducing lead times while st…
Apollomics Inc. reported its full year 2025 financial results, highlighting significant progress in its oncology pipeline, particularly with its lead drug vebreltinib. The company is advancing global clinical trials for vebreltinib, a selective c-MET inhibitor approved in China for multiple indications, and plans to submit an IND application in the…
Terra Innovatum highlights the U.S. Nuclear Regulatory Commission's advancement of draft Part 57 rulemaking aimed at enabling efficient, scalable deployment of standardized microreactor systems. The Company’s SOLO™ Micro-Modular Reactor design aligns closely with the new risk-informed, performance-based licensing framework, positioning Terra Innova…
Opus Genetics announced that its leadership team will present encouraging preliminary and preclinical data on its gene therapy programs for inherited retinal diseases at multiple prestigious medical conferences in May 2026. This includes updates on Phase 1b/2a clinical trials for LCA5 and BEST1 gene therapies, highlighting advancements toward durab…
